While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, ...

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

The issuer is solely responsible for the content of this announcement.

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce inflammation and improve heart health. With such advantages, the demand ...

Here are five questions answered about the FDA's decision to halt compounded versions of GLP-1 drugs. The FDA says state-licensed compounding pharmacies must immediately stop making most compound ...

Using Bullish Candlestick Patterns To Buy Stocks Gauging the Strength of a Market Move Stochastics: An Accurate Buy and Sell Indicator Candlestick charts are a cornerstone in technical analysis ...

Popular weight-loss drugs like Ozempic (generic name: semaglutide), which are intended for people with type 2 diabetes and also known as GLP-1 agonist drugs, may be beneficial for brain health, but ...

Minnesota could be a leader in requiring coverage of GLP-1 drugs for obesity Increasing access to these effective evidence-based treatments would benefit our society as a whole, not just those ...